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Biacore offers a versatile, label-free technology for detailed studies of 
biomolecular interactions, from early research to drug discovery and development and 
on to QC. 
Biacore delivers high quality kinetic, affinity, concentration, specificity, 
selectivity, and thermodynamic interaction data – in real time with exceptional 
sensitivity. It is possible to  obtain high quality kinetics from the fastest on-rates to the 
slowest off-rates, analyze interactions involving the smallest low molecular weight 
(LMW) compounds, process up to 384 samples in unattended runs, get to the final result 
faster using guided workflows with built-in data quality assessments and tools, such as 
single cycle kinetics and calibration-free concentration analysis. Moreover dedicated 
tools for confident immunogenicity test or recover samples for identification by mass 
spectrometry can be applied thus widening the field of application for label-free 
technology. For this last application, Biacore T200 in combination with mass 
spectrometry provides the possibility to identify proteins on the basis of functional 
binding criteria. Sample recovery and digestion are supported by the software. Among 
the possible applications, we will show some examples of how Biacore technology 
coupled to mass spectrometry can help to resolve some bottlenecks in proteomics. 
As conclusion, with this technology we increase understanding of molecular 
mechanisms and structure-function relationships, define potential drug targets and 
diagnostic markers, select and characterize biotherapeutic candidates, select and 
optimize lead compounds during drug discovery, detect and characterize anti-drug 
antibodies (ADA) in immunogenicity studies or perform time- and cost-efficient 
concentration analysis in vaccine development.  
 
